Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

BIIB022

Known as: Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022, BIIB-022 
A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors
SummaryPurpose The IGF-1R signaling pathway has been implicated in multiple cancers as important for cell survival, proliferation… 
  • table 3
  • table 1
  • table 2
  • figure 1
  • figure 2
Review
2012
Review
2012
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors.
The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling components have become increasingly… 
Review
2011
Review
2011
Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review
  • E. Ozkan
  • Molecular and Cellular Endocrinology
  • 2011
  • Corpus ID: 37296132
Cancer database analysis indicates that prostate cancer is one of the most seen cancers in men meanwhile composing the leading… 
2010
2010
Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.
2612 Background: The IGF pathway is believed to play a key role in the pathogenesis of several tumors. BIIB022 is a human… 
Review
2009
Review
2009
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
The insulin-like growth factor 1 receptor (IGF-1R) and its associated signalling system has provoked considerable interest over… 
2009
2009
Dyax and Biogen Idec Expand Drug Discovery Deal
Biogen Idec has expanded its agreement to discover additional antibody products using Dyax’s phage display drug discovery… 
2009
2009
1227 A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumours
2008
2008
BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and Rapamycin in…
4002 Antibodies to IGF-1R as inhibitors of PI3K/AKT survival pathway have shown evidence of objective responses in early clinical… 
2007
2007
BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy
B210 Antibodies targeting human type I insulin-like growth factor receptor (IGF-1R) as inhibitors of tumor survival pathway have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE